Safety & Performance of CANOpus PINtuition Surgical Marker Navigation

NCT ID: NCT06950021

Last Updated: 2025-04-29

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-01
• Study Completion Date: 2026-02-01

Brief Summary

The goal of this clinical trial is to evaluate the safety and performance of the Canopus Marker in adult breast cancer patients who are scheduled for breast-conserving surgery. The main questions it aims to answer are:

1. Can the Canopus Marker be safely and effectively used to mark tissue for surgical removal?

2. What is the satisfaction level of radiologists, surgeons, and patients with the use of the Canopus Marker?

Participants will:

• Have the Canopus Marker implanted into the tumor or nearby tissue using ultrasound guidance.
• Undergo surgery where the Canopus Marker will help guide the surgeon to the tumor, and the marker will be removed along with the tumor. This surgery is performed using an FDA cleared and CE-marked detection device (Sirius Pintuition Detector).
• Attend a follow-up visit two weeks after surgery to assess any adverse events and overall satisfaction.

Detailed Description

Breast cancer remains one of the most prevalent malignancies affecting women worldwide, necessitating a range of treatment modalities to manage and combat the disease effectively. These modalities include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Among these, breast-conserving surgery (BCS), also known as lumpectomy, has become a cornerstone of breast cancer treatment. BCS involves the removal of the cancerous tissue while preserving as much of the breast as possible. This approach aims to achieve oncologic safety comparable to mastectomy while offering psychological and cosmetic benefits. The success of BCS has been augmented by advancements in imaging techniques and surgical tools, facilitating precise tumour localization and excision.

Over the years, various localization technologies have been developed to enhance the precision of breast cancer surgeries. Traditional methods like wire localization have been widely used but are often associated with discomfort and logistical challenges. Advances in medical technology have led to non-wire localization methods such as radioactive seed localization (RSL) and radar systems. The commercially available Sirius Pintuition system, using magnetic seed localization, involves inserting a small magnetic marker into the tumour site, detectable with a magnetic probe during surgery. This system aims to offer advantages like improved subject comfort, precise localization, and ease of use for surgeons. The investigational Canopus Marker, building on Sirius Pintuition's success, aims to further improve the precision and effectiveness of breast-conserving surgeries. The Canopus Marker incorporates additional anchoring mechanisms designed to enhance its stability during breast-conserving surgeries. These enhancements aim to mitigate any potential risk of dislodgement, while maintaining the marker's detectability and ease of use for surgeons.

The present investigation is only evaluating if the additional anchors added to the Pintuition Marker, which is the Canopus Marker, is also safe and performing as intended. Therefore, the present investigation will be similar in design as the study that was conducted to obtain the Pintuition System's CE mark. That is, a single-arm, open-label study in one centre in The Netherlands. The sample size (n=35) is determined to demonstrate that the Canopus Marker does not perform worse than the Pintuition Marker and other similar marker-based localization devices.

Conditions

Breast Surgery; Lymph Node Excision

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Primary breast lesion and/or axillary lymph node localisation prior to surgical excision

Device: CANOPUS Magnetic Marker by Sirius Medical Systems B.V.

Placement of experimental device in primary breast lesion and/or axillary lymph node indicated for surgical removal and requiring localisation

Group Type: EXPERIMENTAL

Magnetic seed

Intervention Type: DEVICE

All patients enrolled will receive a single Sirius Canopus Marker with two anchors added to it for improved tissue fixation. Implantation will be done by a radiologist before breast conserving surgery, usually scheduled within a few days after Canopus Marker implantation. The Canopus Marker is removed with the specimen during the surgery.

Interventions

Magnetic seed

All patients enrolled will receive a single Sirius Canopus Marker with two anchors added to it for improved tissue fixation. Implantation will be done by a radiologist before breast conserving surgery, usually scheduled within a few days after Canopus Marker implantation. The Canopus Marker is removed with the specimen during the surgery.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject is willing and able to provide informed consent for the investigation

2. Subject is at least 18 years of age

3. Subject is diagnosed with a single, pathologically confirmed unifocal breast tumour (DCIS or invasive)

4. Tumour is ultrasound visible

5. Subject is indicated for primary breast conserving surgery and/or targeted axillary dissection

6. Subject is indicated for preoperative localization using a single marker in the primary breast lesion and/or a single marker in an axillary lymph node

Exclusion Criteria

1. Subject is lactating or pregnant

2. Subject is expected to have surgery scheduled more than 6 weeks after implantation of the Canopus Marker.

3. Subject has an ICD or other active implant such as a pacemaker less than 5 cm away from the intended target location(s)

4. Subject has a proven infection or clinically significant hematoma at or close to the intended target location(s)

5. Subject is expected to require an MRI scan in the period between implantation and surgery

6. Known hypersensitivity to Titanium or Nickel

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Avania B.V.

UNKNOWN

Sponsor Role: collaborator

Sirius Medical Systems B.V.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Rode Kruis Ziekenhuis

Beverwijk, North Holland, Netherlands

Countries

Netherlands

Central Contacts

Bram Schermers, CEO/CTO

Role: CONTACT

bram.schermers@sirius-medical.com

+31 6 48044508

Kitty Kempen Kempen, PhD, Clinical Affairs Director

Role: CONTACT

kitty.kempen@sirius-medical.com

+31 6 10223238

Facility Contacts

Carlinda Bresser, Research Coordinator

Role: primary

Other Identifiers

NL-MF-000010932

Identifier Type: OTHER

Identifier Source: secondary_id

CANOPIN

Identifier Type: -

Identifier Source: org_study_id